The Committee will discuss Cidara Therapeutics New Drug Application (NDA) 217417 for Rezafungin Lyophilized powder for injection for treatment of candidemia and invasive candidiasis in adults in a virtual meeting being held on January 24 at 9 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDTX:
- Cidara Therapeutics nominates first oncology candidate from Cloudbreak platform
- Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
- Cidara Therapeutics announces issuance of first U.S. patent for CD388
- Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
- Cidara announces two proxy firms recommend vote “FOR” reverse stock split